stockrowProtagonist Therapeutics, Inc. (PTGX) vs Spyre Therapeutics, Inc. (SYRE)
- Protagonist Therapeutics, Inc. PTGX 133.89 −1.01%
- Spyre Therapeutics, Inc. SYRE 101.95 +5.55%
Protagonist Therapeutics, Inc. and Spyre Therapeutics, Inc. are both Biotechnology companies. Protagonist Therapeutics, Inc. and Spyre Therapeutics, Inc. are of similar size ($9.2B and $8.8B). Spyre Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Protagonist Therapeutics, Inc. trades at 111×. Protagonist Therapeutics, Inc. grew revenue faster over the last twelve months: 34.8% against −81.8%. Protagonist Therapeutics, Inc. has the higher net margin (29.4% vs 0.00%) and the higher return on invested capital (61.8% vs 0.00%). Across the 16 metrics below, Protagonist Therapeutics, Inc. leads on 13 and Spyre Therapeutics, Inc. on 3.
Valuation
Profitability
| Metric | PTGX | SYRE | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | 20.69% | 0.00% | 0.00% |
| Net margin | 29.40% | 0.00% | 0.00% |
| Free cash flow margin | 46.31% | 0.00% | 0.00% |
| Return on equity | 10.98% | (41.15%) | (50.12%) |
| Return on assets | 10.34% | (30.89%) | (45.60%) |
| Return on invested capital | 61.84% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack